PL2711371T3 - Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun - Google Patents

Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun

Info

Publication number
PL2711371T3
PL2711371T3 PL13198584T PL13198584T PL2711371T3 PL 2711371 T3 PL2711371 T3 PL 2711371T3 PL 13198584 T PL13198584 T PL 13198584T PL 13198584 T PL13198584 T PL 13198584T PL 2711371 T3 PL2711371 T3 PL 2711371T3
Authority
PL
Poland
Prior art keywords
pregnane
manufacture
treatment
pharmaceutical composition
cns disorders
Prior art date
Application number
PL13198584T
Other languages
English (en)
Inventor
Torbjörn BÄCKSTRÖM
Gianna Ragagnin
Original Assignee
Asarina Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asarina Pharma Ab filed Critical Asarina Pharma Ab
Publication of PL2711371T3 publication Critical patent/PL2711371T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13198584T 2006-11-21 2007-11-20 Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun PL2711371T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
EP07835459.4A EP2097437B1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
EP13198584.8A EP2711371B1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders

Publications (1)

Publication Number Publication Date
PL2711371T3 true PL2711371T3 (pl) 2018-06-29

Family

ID=39429970

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14154304T PL2792681T3 (pl) 2006-11-21 2007-11-20 Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń CNS
PL07835459T PL2097437T3 (pl) 2006-11-21 2007-11-20 Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN
PL13198584T PL2711371T3 (pl) 2006-11-21 2007-11-20 Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL14154304T PL2792681T3 (pl) 2006-11-21 2007-11-20 Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń CNS
PL07835459T PL2097437T3 (pl) 2006-11-21 2007-11-20 Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN

Country Status (16)

Country Link
US (9) US8580983B2 (pl)
EP (4) EP2792681B1 (pl)
JP (5) JP5386362B2 (pl)
AU (1) AU2007322423C1 (pl)
BR (2) BRPI0718945B8 (pl)
CA (2) CA2664126C (pl)
DK (3) DK2097437T3 (pl)
ES (3) ES2662500T3 (pl)
HU (3) HUE026961T2 (pl)
IN (1) IN2014DN02014A (pl)
MX (1) MX2009005335A (pl)
PL (3) PL2792681T3 (pl)
PT (1) PT2097437E (pl)
RU (1) RU2458065C2 (pl)
SI (1) SI2097437T1 (pl)
WO (1) WO2008063128A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2097437T3 (en) * 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
MX2012008257A (es) 2010-01-14 2012-11-21 Umecrine Mood Ab Una composicion farmaceutica que comprende 3-beta-hidroxi-5-alfa-p regnan-20-ona con propiedades mejoradas de almacenamiento y solubilidad.
EP2566482A1 (en) * 2010-05-07 2013-03-13 Institut National de la Santé et de la Recherche Médicale Progesterone receptor antagonists and uses thereof
EP3176176A1 (en) * 2012-11-28 2017-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
EP3932932A1 (en) 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
AU2015212606B2 (en) * 2014-01-29 2019-11-21 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
EP3719029A1 (en) * 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
AR103384A1 (es) * 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
CA2991313C (en) 2015-07-06 2023-12-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
AU2017240157B2 (en) 2016-04-01 2022-10-20 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
NZ752732A (en) 2016-10-18 2024-08-30 Sage Therapeutics Inc Oxysterols and methods of use thereof
AU2017345399B2 (en) 2016-10-18 2022-02-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
KR102478510B1 (ko) 2017-02-10 2022-12-16 아사리나 파마 아베 의학적 치료에서 사용하기 위한 3-베타-히드록시-5-알파-프레그난-20-온
EP3716954A1 (en) 2017-11-27 2020-10-07 Umecrine Cognition AB Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime
CA3094026A1 (en) 2018-04-05 2019-10-10 Asarina Pharma Aps Gaba-a antagonists for treating substance withdrawal disorders
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
EP4430056A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
EP4430057A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
EP4389129A1 (en) 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) * 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL112638A (en) * 1994-02-14 2003-10-31 Cocensys Inc 3alpha-HYDROXYLATED PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CN1171114A (zh) * 1994-11-23 1998-01-21 科斯赛斯公司 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
CZ394197A3 (cs) 1995-06-06 1998-06-17 Cocensys, Inc. Neuroaktivní steroidy androstanové a pregnanové řady
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE69927960T2 (de) 1998-03-11 2006-07-20 Torbjörn Backström Epiallopregnanolon zur behandlung von krankheiten des cns
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
JP4914368B2 (ja) * 2004-11-18 2012-04-11 ウメクライン アーベー Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用
DK2097437T3 (en) 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
EP2566482A1 (en) 2010-05-07 2013-03-13 Institut National de la Santé et de la Recherche Médicale Progesterone receptor antagonists and uses thereof

Also Published As

Publication number Publication date
IN2014DN02014A (pl) 2015-07-10
JP2013173781A (ja) 2013-09-05
PT2097437E (pt) 2015-09-15
BR122013033954B1 (pt) 2021-01-12
US20130102578A1 (en) 2013-04-25
JP5657052B2 (ja) 2015-01-21
EP2711372A1 (en) 2014-03-26
ES2543841T3 (es) 2015-08-24
HUE036410T2 (hu) 2018-07-30
JP5918170B2 (ja) 2016-05-18
US20150315231A1 (en) 2015-11-05
JP5386362B2 (ja) 2014-01-15
US20080119416A1 (en) 2008-05-22
RU2458065C2 (ru) 2012-08-10
BR122013033954B8 (pt) 2021-05-25
EP2792681A1 (en) 2014-10-22
DK2711371T3 (en) 2018-04-16
AU2007322423B2 (en) 2013-01-10
HUE026961T2 (en) 2016-07-28
CA2833976C (en) 2016-03-15
ES2662500T3 (es) 2018-04-06
AU2007322423C1 (en) 2013-08-15
US20140011792A1 (en) 2014-01-09
JP2013177411A (ja) 2013-09-09
US8853190B2 (en) 2014-10-07
DK2097437T3 (en) 2015-06-29
ES2607852T3 (es) 2017-04-04
US20160272670A1 (en) 2016-09-22
BRPI0718945B1 (pt) 2020-10-13
BRPI0718945A2 (pt) 2013-12-24
EP2711371B1 (en) 2018-01-10
US20140011793A1 (en) 2014-01-09
JP2010510210A (ja) 2010-04-02
BRPI0718945B8 (pt) 2021-05-25
US8580983B2 (en) 2013-11-12
JP2013173782A (ja) 2013-09-05
MX2009005335A (es) 2009-06-08
SI2097437T1 (sl) 2015-10-30
EP2097437B1 (en) 2015-05-27
PL2792681T3 (pl) 2017-06-30
PL2097437T3 (pl) 2015-12-31
CA2664126A1 (en) 2008-05-29
DK2792681T3 (en) 2017-01-23
HUE033037T2 (hu) 2017-11-28
JP2015147774A (ja) 2015-08-20
AU2007322423A1 (en) 2008-05-29
BRPI0718945A8 (pt) 2017-09-19
US20130102579A1 (en) 2013-04-25
EP2097437A4 (en) 2012-12-26
US20140011779A1 (en) 2014-01-09
RU2009107537A (ru) 2010-12-27
EP2792681B1 (en) 2016-10-19
CA2833976A1 (en) 2008-05-29
CA2664126C (en) 2014-04-29
WO2008063128A1 (en) 2008-05-29
EP2711371A1 (en) 2014-03-26
EP2097437A1 (en) 2009-09-09
US20130281421A1 (en) 2013-10-24
US9200028B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
HUE036410T2 (hu) Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására
PT1919450E (pt) Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
SI2027140T1 (sl) Industrijski proces za sintezo 17 alfa -acetoksi-11 beta -(4-(n,n- dimetil-amino)-fenil)-19-norpregna-4,9-dien-3,20-diona in novi intermediati postopka
EP2099449A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE
HK1133651A1 (en) Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
EP1986639A4 (en) PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
IL213959A0 (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP1988777A4 (en) PYRAZOLE FOR THE TREATMENT OF ADIPOSITAS AND OTHER CNS DISEASES
EP2318005A4 (en) NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2044108A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
EP2077838A4 (en) METHODS FOR TREATING A-RELATED DISORDERS AND COMPOSITIONS THEREFOR
EP2004216A4 (en) AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
HK1137357A1 (en) Use of a composition comprising formoterol and beclometasone dipropionate in the manufacture of a pharmaceutical for the prevention and or treatment of an exacerbation of asthma
IL200044A (en) Tricyclic compounds as modulators of a glucocorticoid receptor and their use in the preparation of drugs for the treatment of diseases
EP2403501A4 (en) PREGNENOLONSULFATE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
IL202205A (en) Process for the preparation of steroids converted at position 17α by 3-hydroxypropyl and at position 17ß - by hydroxy from the corresponding 14-oxo history and intermediates obtained in this process
IL204957A (en) Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten
AU2006906505A0 (en) Agent for the treatment of hormone-dependent disorders and uses thereof
HU0600815D0 (en) Pharmaceutical composition for the treatment of obstructive and inflammatory disorders of the respiratory tract
PL380320A1 (pl) Sposób wytwarzania 1,4-pregnadien-17,21-diol- 3,20-dionu